menu
    • menu

    Company profile for Ribomic

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company’s core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs...
    RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company’s core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other problems. See RIBOMIC website for more information.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ribomicjapan Flag
    Country
    Country
    Japan
    Address
    Address
    Shirokanedai Usui Bldg. 6F 3-16-13 Shirokanedai, Minato-ku Tokyo 108-0071
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ribomic.com/eng/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RIBOMIC Reports Ph2 Data Showing +5cm Growth With Umedaptanib
    RIBOMIC Reports Ph2 Data Showing +5cm Growth With Umedaptanib

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/ribomic-announces-positive-phase-2-cohort-2-results-for-umedaptanib-pegol-in-achondroplasia-demonst

    PHARMIWEB
    07 Oct 2025
    Share Share
    Nucleic Acid Aptamer Pharmacokinetics Extended in Joint Research
    Nucleic Acid Aptamer Pharmacokinetics Extended in Joint Research

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/successful-extension-of-nucleic-acid-aptamer-pharmacokinetics-in-joint-research-by-ajinomoto-co-inc-and-ribomic-inc-302447922.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Riboimic Phase IIa Results: Umedaptanib Pegol in Achondroplasia
    Riboimic Phase IIa Results: Umedaptanib Pegol in Achondroplasia

    05 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241105303837/en

    BUSINESSWIRE
    05 Nov 2024
    Share Share
    Ribomic Completes Enrollment For Umedaptanib Pegol Achondroplasia Study
    Ribomic Completes Enrollment For Umedaptanib Pegol Achondroplasia Study

    03 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240803260151/en

    BUSINESSWIRE
    03 Aug 2024
    Share Share
    RIBOMIC Phase I and II Data Published in the Eye
    RIBOMIC Phase I and II Data Published in the Eye

    05 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231204246876/en

    BUSINESSWIRE
    05 Dec 2023
    Share Share
    RIBOMIC Completes IND Submission for Phase 2 Trial of RBM-007 in Achondroplasia
    RIBOMIC Completes IND Submission for Phase 2 Trial of RBM-007 in Achondroplasia

    19 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220419005547/en

    BUSINESSWIRE
    19 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search